ES2086644T3 - Preparado anovulatorio para la contracepcion hormonal. - Google Patents

Preparado anovulatorio para la contracepcion hormonal.

Info

Publication number
ES2086644T3
ES2086644T3 ES92250018T ES92250018T ES2086644T3 ES 2086644 T3 ES2086644 T3 ES 2086644T3 ES 92250018 T ES92250018 T ES 92250018T ES 92250018 T ES92250018 T ES 92250018T ES 2086644 T3 ES2086644 T3 ES 2086644T3
Authority
ES
Spain
Prior art keywords
hormonal
component
preparation
units
anovulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92250018T
Other languages
English (en)
Other versions
ES2086644T5 (es
Inventor
Marika Dr Med Ehrlich
Herbert Prof Dr Kuhl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6424973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2086644(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of ES2086644T3 publication Critical patent/ES2086644T3/es
Application granted granted Critical
Publication of ES2086644T5 publication Critical patent/ES2086644T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EL MEDIO QUE IMPIDE LA OVULACION QUE SIRVE PARA LA CONTRACEPCION HORMONAL DISPONE DE DOS COMPONENTES HORMONALES QUE SE ADMINISTRAN DE FORMA ORAL Y QUE ESTAN COLOCADOS EN UNA CAJA QUE LOS MANTIENE SEPARADOS. EL PRIMER COMPONENTE ES UN PREPARADO OSTROGENAL QUE INFLUYE EXCLUSIVAMENTE EN LA DISTORSION DE LA MADUREZ DEL FOLICULO. EL SEGUNDO COMPONENTE CONTIENE UNA COMBINACION DEL PREPARADO OSTROGENAL Y DE OTRO PREPARADO QUE DOSIFICA LA OVULACION. ESTOS COMPONENTES SE CARACTERIZAN PORQUE EL NUMERO TOTAL DE LAS UNIDADES HORMONALES ES IGUAL QUE EL DEL PERIODO. EL PRIMER COMPONENTE HORMONAL TIENE DE 5 A 14 UNIDADES Y EL SEGUNDO COMPONENTE HORMONAL TIENE DE 23 A 14 UNIDADES. EL NUMERO DE UNIDADES DIARIAS DEL PRIMER COMPONENTE HORMONAL ES MENOR QUE EL NUMERO DE UNIDADES DIARIAS QUE EL SEGUNDO COMPONENTE HORMONAL.
ES92250018T 1991-02-09 1992-01-22 Preparado anovulatorio para la contracepcion hormonal. Expired - Lifetime ES2086644T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4104385A DE4104385C1 (es) 1991-02-09 1991-02-09

Publications (2)

Publication Number Publication Date
ES2086644T3 true ES2086644T3 (es) 1996-07-01
ES2086644T5 ES2086644T5 (es) 2002-11-16

Family

ID=6424973

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92250018T Expired - Lifetime ES2086644T5 (es) 1991-02-09 1992-01-22 Preparado anovulatorio para la contracepcion hormonal.

Country Status (16)

Country Link
US (2) US5280023A (es)
EP (1) EP0499348B2 (es)
JP (1) JP2852985B2 (es)
AT (1) ATE136781T1 (es)
AU (2) AU669327B2 (es)
BR (1) BR9204121A (es)
CA (1) CA2079002C (es)
DE (2) DE4104385C1 (es)
DK (1) DK0499348T4 (es)
ES (1) ES2086644T5 (es)
FI (1) FI98888C (es)
GR (1) GR3019833T3 (es)
HU (1) HU218663B (es)
NO (1) NO179696C (es)
RU (1) RU2091069C1 (es)
WO (1) WO1992013539A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4224534A1 (de) * 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4313926A1 (de) * 1993-04-28 1994-11-03 Jenapharm Gmbh Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE4321957C2 (de) * 1993-07-01 1995-09-28 Marika Dr Med Ehrlich Verwendung eines hormonalen Mittels zur Therapie der Akne
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
DE4405591C1 (de) * 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonsubstitution
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19504227C2 (de) * 1995-02-09 1999-04-29 Klaus Dr Med Umbreit Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
JP2001513566A (ja) * 1997-08-27 2001-09-04 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 経口避妊における、エストロゲンと子宮内膜節約性プロゲスチンおよび子宮内膜萎縮性プロゲスチンとの組み合わせ物
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US7989436B2 (en) * 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
NZ591627A (en) 2001-12-05 2012-09-28 Teva Womens Health Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US6992075B2 (en) 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
CA2521471A1 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
NZ545130A (en) * 2003-07-16 2009-03-31 Duramed Pharmaceuticals Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
DE102004026671A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20060100566A1 (en) * 2004-11-05 2006-05-11 Women's Medical Research Group, Llc Apparatus and method for the treatment of dysmenorrhea
EP1853272A1 (en) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US7704984B2 (en) 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6615481A (es) † 1966-11-02 1968-05-03
US3639600A (en) † 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US3733407A (en) * 1971-08-25 1973-05-15 Syntex Corp Menopause treatment
DE2431704A1 (de) * 1974-07-02 1976-01-22 Asche Ag Stufenkombinationspraeparate per kontrazeption
DE2645307A1 (de) * 1976-10-05 1978-04-06 Schering Ag Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
AU630334B2 (en) * 1987-09-24 1992-10-29 Jencap Research Ltd. Hormone preparations for hormone replacement therapy and contraceptive method
EP0368373A1 (en) * 1988-10-13 1990-05-16 Akzo Nobel N.V. Multi-phase contraceptive preparation

Also Published As

Publication number Publication date
NO923874D0 (no) 1992-10-05
EP0499348B2 (de) 2002-03-27
DK0499348T4 (da) 2002-06-10
EP0499348B1 (de) 1996-04-17
CA2079002A1 (en) 1992-08-10
ATE136781T1 (de) 1996-05-15
FI924519L (fi) 1992-10-07
US5510341A (en) 1996-04-23
ES2086644T5 (es) 2002-11-16
RU2091069C1 (ru) 1997-09-27
CA2079002C (en) 1998-07-28
AU692376B2 (en) 1998-06-04
EP0499348A1 (de) 1992-08-19
DE59205986D1 (de) 1996-05-23
JP2852985B2 (ja) 1999-02-03
US5280023A (en) 1994-01-18
NO923874L (no) 1992-10-05
HU9203197D0 (en) 1992-12-28
AU669327B2 (en) 1996-06-06
JPH0558909A (ja) 1993-03-09
WO1992013539A1 (de) 1992-08-20
FI98888C (fi) 1997-09-10
GR3019833T3 (en) 1996-08-31
NO179696C (no) 1996-12-04
FI98888B (fi) 1997-05-30
HU218663B (hu) 2000-10-28
HUT64229A (en) 1993-12-28
AU5053896A (en) 1996-06-27
AU1191092A (en) 1992-09-07
DE4104385C1 (es) 1992-08-13
BR9204121A (pt) 1993-06-08
FI924519A0 (fi) 1992-10-07
NO179696B (no) 1996-08-26
DK0499348T3 (da) 1996-08-12

Similar Documents

Publication Publication Date Title
ES2086644T3 (es) Preparado anovulatorio para la contracepcion hormonal.
MX9102501A (es) Derivados de metano sulfonamida, composiciones farderivados de metanosulfonamida, composiciones farmaceuticas que los contienen y procedimiento para smaceuticas que los contienen y procedimiento para u preparacion. su preparacion.
MX9202289A (es) Nuevos derivados de tiopiranopirrol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2075202T3 (es) Nuevas arilpiridazinas, su preparacion, su utilizacion, y medicamentos que las contienen.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2146297T3 (es) Nuevos derivados del benzopirano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
PT951473E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
MX9206503A (es) Nuevos derivados de lupano, proceso para su preparacion y composicion farmaceutica que los contiene.
ES2100046T3 (es) Composiciones antipireticas y analgesicas que contienen r-ketorolaco opticamente puro.
AR012417A1 (es) COMPOSICIoN FARMACÉUTICA DE ADMINISTRACIoN ORAL Y PROCEDIMIENTO PARA SU PRODUCCION.
ES2142432T3 (es) Forma de dosificacion de la gepirona.
MX9202152A (es) Derivados del indol, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9102580A (es) Nuevas benzodiacepinonas, procedimiento para su preparacion y composicion farmaceutica que las contiene.
ES2055014T3 (es) Productos que contienen psyllium.
ES2163896T3 (es) Composiciones para aumentar la concentracion y/o motilidad de los espermatozoos en humanos.
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
ECSP941120A (es) Derivados de 1,5 benzodiazepina
ES2020171T3 (es) Eteres de 1-bencil-3-hidroximetilindazol con 2-hidroxiacidos alifaticos.
FI943645A7 (fi) Uusia bakkatiini-III ja 10-deasetyylibakkatiini-III-johdannaisia, niid en valmistus ja niitä sisältäviä farmaseuttisia koostumuksia

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 499348

Country of ref document: ES